Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer's disease
Abstract
Objective: To delineate the features of regional cerebral metabolic rate of glucose(CMRglc) in dementia with Lewy bodies (DLB).
Methods: We compared absolute CMRglc in 12 patients with a clinical diagnosis of DLB, 12 patients with a clinical diagnosis of Alzheimer's disease (AD), and 12 normal volunteers (NC), using 18F-fluorodeoxyglucose (FDG) and PET. The three groups were matched for age and sex, and there were no differences in disease duration or severity of cognitive disturbances between the DLB and AD groups.
Results: CMRglc was significantly lower in patients with DLB than in that of NC in most parts of the brain, except the sensorimotor cortices, basal ganglia, thalamus, and pons. Between the DLB and AD groups, there were significant regional CMRglc differences in the medial and lateral occipital lobes. In DLB and AD, the CMRglc reduction patterns were similar, though the global metabolic reduction was larger in DLB, and the occipital CMRglc reduction in DLB could differentiate DLB from AD. The relative occipital CMRglc(normalized to the sensorimotor CMRglc) was a useful measure for the differential diagnosis of DLB from AD. The sensitivity and the specificity were 92% when using the minimal value of the normalized occipital CMRglc in the NC group as the cut-off point.
Conclusion: These different regional CMRglc reductions substantiate the pathologic, neurochemical, and clinical differences between DLB and AD.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47:1113-1124.
2.
Mega MS, Masterman DL, Benson DF, et al. Dementia with Lewy bodies: reliability and validity of clinical and pathologic criteria. Neurology 1996;47:1403-1409.
3.
Albin RL, Minoshima S, D'Amato CJ, Frey KA, Kuhl DA, Sima AAF. Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease. Neurology 1996;47:462-466.
4.
Borght VT, Minoshima S, Giordani B, et al. Cerebral metabolic differences in Parkinson's and Alzheimer's diseases matched for dementia severity. J Nucl Med 1997;38:797-802.
5.
Imamura T, Ishii K, Sasaki M, et al. Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer's disease: a comparative study using positron emission tomography. Neurosci Lett 1997;235:49-52.
6.
Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
7.
Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-2314.
8.
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Standlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
9.
Ishii K, Sasaki M, Kitagaki H, et al. Reduction of cerebellar glucose metabolism in advanced Alzheimer's disease. J Nucl Med 1997;38:925-928.
10.
Phelps ME, Huang SC, Hoffman EJ, Selin C, Sokoloff L, Kuhl DE. Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-D-glucose: validation of method. Ann Neurol 1979;6:371-388.
11.
Ishii K, Sasaki M, Kitagaki H, Sakamoto S, Yamaji S, Maeda K. Regional difference of cerebral blood flow and oxidative metabolism in human cortex. J Nucl Med 1996;37:1086-1088.
12.
Ardekani BA, Braun M, Hutton BF, Kanno I, Iida H. A fully automatic multimodality image registration algorithm. J Comput Assist Tomogr 1995;18:615-623.
13.
Goto I, Taniwaki T, Hosokawa S, Otsuka M, Ichiya Y, Ichimiya A. Positron emission tomographic (PET) studies in dementia. J Neurol Sci 1993;114:1-6.
14.
Peppard RF, Martin WR, Carr GD, et al. Cerebral glucose metabolism in Parkinson's disease with and without dementia. Arch Neurol 1992;49:1262-1268.
15.
Flynn DD, Mash DC. Distinct kinetic binding properties of N-[3H]-methylscopolamine afford differential labeling and localization of M1, M2, and M3 muscarinic receptor subtypes in primate brain. Synapse 1993;14:283-296.
16.
Ferrari-Dileo G, Waelbroeck M, Mash DC, Flynn DD. Selective labeling and localization of the M4 (m4) muscarinic receptor subtype. Molecular Pharmacol 1994;46:1028-1035.
17.
Langlaris PJ, Thal L, Hansen L, Galasko D, Alford M, Masliah E. Neurotransmitters in basal ganglia and cortex of Alzheimer's disease with and without Lewy bodies. Neurology 1993;43:1927-1934.
18.
Perry EK, Haroutunian V, Davis KL, et al. Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease. Neurol Rep 1994;5:747-749.
19.
Kosaka K. Diffuse Lewy body disease in Japan. J Neurol 1990;237:197-204.
20.
Perry RH, Irving D, Blessed G, Fairbairn A, Perry EK. Senile dementia of Lewy body type. A clinically and neuropathologically distinct form of Lewy body dementia in the elderly. J Neurol Sci 1990;95:119-139.
21.
Förstl H, Burns A, Luthert P, Cairns N, Levy R. The Lewy-body variant of Alzheimer's disease. Clinical and pathological findings. Br J Psychiatry 1993;162:385-392.
22.
Gnanalingham KK, Byrne EJ, Thornton A. Clock-face drawing to differentiate Lewy body and Alzheimer type dementia syndromes. Lancet 1996;347:696-697.
23.
Hansen L, Salmon D, Galasko D, et al. The Lewy body variant of Alzheimer's disease: a clinical and pathologic entity. Neurology 1990;40:1-8.
24.
Salmon DP, Galasko D, Hansen LA, et al. Neuropsychological deficits associated with diffuse Lewy body disease. Brain Cogn 1996;31:148-165.
25.
Perry RH, McKeith IG, Perry EK. Dementia with Lewy bodies. In: Perry EK, Perry RH, eds. Altered Consciousness and Transmitter Signaling in Lewy Body Dementia. Cambridge, UK: Cambridge University Press; 1996:397-413.
26.
Perry EK, Morris CM, Court JA, et al. Alteration in nicotine binding sites in Parkinson's disease, Lewy body dementia and Alzheimer's disease: possible index of early neuropathology. Neuroscience 1995;64:385-395.
27.
Yamamoto T, Imai T. A case of diffuse Lewy body and Alzheimer's diseases with periodic synchronous discharges. J Neuropathol Exp Neurol 1988;47:536-548.
28.
Lippa CF, Smith TW, Swearer JM. Alzheimer's disease and Lewy body disease: a comparative clinicopathological study. Ann Neurol 1994;35:81-88.
29.
Minoshima S, Frey KA, Foster NL, Kuhl DE. Preserved pontine glucose metabolism in Alzheimer disease: a reference region for functional brain image (PET) analysis. J Comput Assist Tomogr 1995;19:541-547.
30.
Hirono N, Mori E, Ishii K, et al. Frontal lobe hypometabolism and depression in Alzheimer's disease. Neurology 1998;50:380-383.
31.
Ishii K, Yamaji S, Mori E. Cerebellar metabolic reduction in Alzheimer's disease and data normalization. J Nucl Med 1998;39:375-376. Letter.
Information & Authors
Information
Published In
Copyright
© 1998.
Publication History
Published online: July 1, 1998
Published in print: July 1998
Authors
Metrics & Citations
Metrics
Citation information is sourced from Crossref Cited-by service.
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Cited By
- Metallomic analysis of brain tissues distinguishes between cases of dementia with Lewy bodies, Alzheimer’s disease, and Parkinson’s disease dementia, Frontiers in Neuroscience, 18, (2024).https://doi.org/10.3389/fnins.2024.1412356
- Right anterior insula ASL hypoperfusion as a diagnostic biomarker of prodromal and mild dementia with Lewy bodies: preliminary evidence using a Bayesian approach, GeroScience, (2024).https://doi.org/10.1007/s11357-024-01288-9
- Sensitivity and specificity of neuroimaging for the diagnosis of Alzheimer's disease, Dialogues in Clinical Neuroscience, 5, 1, (89-99), (2022).https://doi.org/10.1080/19585969.2022.12130515
- 60 Years of Achievements by KSNM in Neuroimaging Research, Nuclear Medicine and Molecular Imaging, 56, 1, (3-16), (2022).https://doi.org/10.1007/s13139-021-00727-1
- Correlation between noise pareidolia test scores for visual hallucinations and regional cerebral blood flow in dementia with Lewy bodies, Annals of Nuclear Medicine, 36, 4, (384-392), (2022).https://doi.org/10.1007/s12149-022-01717-9
- Alzheimer’s Dementia: The Emerging Role of Positron Emission Tomography, The Neuroscientist, 28, 5, (507-519), (2021).https://doi.org/10.1177/1073858421997035
- FDG PET metabolic signatures distinguishing prodromal DLB and prodromal AD, NeuroImage: Clinical, 31, (102754), (2021).https://doi.org/10.1016/j.nicl.2021.102754
- The value of multimodal imaging with 123I-FP-CIT SPECT in differential diagnosis of dementia with Lewy bodies and Alzheimer's disease dementia, Neurobiology of Aging, 99, (11-18), (2021).https://doi.org/10.1016/j.neurobiolaging.2020.12.009
- Added value of semiquantitative analysis of brain FDG-PET for the differentiation between MCI-Lewy bodies and MCI due to Alzheimer’s disease, European Journal of Nuclear Medicine and Molecular Imaging, 49, 4, (1263-1274), (2021).https://doi.org/10.1007/s00259-021-05568-w
- Alzheimer's disease alters oligodendrocytic glycolytic and ketolytic gene expression, Alzheimer's & Dementia, 17, 9, (1474-1486), (2021).https://doi.org/10.1002/alz.12310
- See more
Loading...
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.
If you need immediate support or to place an order, please call or email customer service:
- 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
- 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
- [email protected]
We appreciate your patience during this time and apologize for any inconvenience.